Research programme: ocular therapeutics - Benitec Biopharma

Drug Profile

Research programme: ocular therapeutics - Benitec Biopharma

Alternative Names: BB 201; BB 202; BB AMD 211; BB AMD 231; TT 211; TT 231

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tacere Therapeutics
  • Developer Benitec Biopharma
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 13 Oct 2016 Preclinical trials in Wet age-related macular degeneration in USA (IV), before October 2016 (Benitec Biopharma pipeline, October 2016)
  • 12 Oct 2016 Benitec Biopharma plans to file an IND application with the US FDA in USA for Age-related macular degeneration in 2017 (Benitec Biopharma Pipeline, October 2016)
  • 12 Oct 2016 Benitec Biopharma plans a phase I/IIa trial for Age-related macular degeneration (Benitec Biopharma Pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top